Protalix completes taliglucerase alfa rolling NDA

Protalix Biotherapeutics Inc. (NYSE-A:PLX) completed submission of a rolling NDA to FDA for taliglucerase alfa to treat Gaucher's disease. Protalix also said it submitted its proposed pediatric investigation plan to EMEA for the plant cell-expressed recombinant form of human glucocerebrosidase (GCase). The submission triggered a $5 million milestone payment from partner Pfizer Inc. (NYSE:PFE), which last week gained exclusive, worldwide rights, excluding Israel, to the compound (See BioCentury, Dec. 07, 2009). ...